These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30287613)

  • 21. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.
    Vu DH; Bolhuis MS; Koster RA; Greijdanus B; de Lange WC; van Altena R; Brouwers JR; Uges DR; Alffenaar JW
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5758-63. PubMed ID: 22926568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.
    Juma SP; Maro A; Pholwat S; Mpagama SG; Gratz J; Liyoyo A; Houpt ER; Kibiki GS; Mmbaga BT; Heysell SK
    BMC Infect Dis; 2019 Feb; 19(1):129. PubMed ID: 30732572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug Resistance Characteristics of
    Wu X; Yang J; Tan G; Liu H; Liu Y; Guo Y; Gao R; Wan B; Yu F
    Front Cell Infect Microbiol; 2019; 9():345. PubMed ID: 31828045
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China.
    Zheng X; Davies Forsman L; Bao Z; Xie Y; Ning Z; Schön T; Bruchfeld J; Xu B; Alffenaar JW; Hu Y
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34737224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
    Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
    Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis.
    Mercier T; Desfontaine V; Cruchon S; Da Silva Pereira Clara JA; Briki M; Mazza-Stalder J; Kajkus A; Burger R; Suttels V; Buclin T; Opota O; Koehler N; Sanchez Carballo PM; Lange C; André P; Decosterd LA; Choong E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Nov; 1211():123456. PubMed ID: 36240540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Investigation of extensive drug resistance in multidrug resistance tuberculosis isolates].
    Bektöre B; Haznedaroğlu T; Baylan O; Ozyurt M; Ozkütük N; Satana D; Cavuşoğlu C; Seber E
    Mikrobiyol Bul; 2013 Jan; 47(1):59-70. PubMed ID: 23390903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.
    Mamatha HG; Shanthi V
    J Glob Antimicrob Resist; 2018 Mar; 12():5-10. PubMed ID: 28887289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyrazinamide Susceptibility and
    Rahman A; Ferdous SS; Ahmed S; Rahman SMM; Uddin MKM; Pholwat S; Gratz J; Houpt E; Banu S
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma.
    Zheng X; Jongedijk EM; Hu Y; Kuhlin J; Zheng R; Niward K; Paues J; Xu B; Davies Forsman L; Schön T; Bruchfeld J; Alffenaar JC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1158():122397. PubMed ID: 33091676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment.
    Kuo CY; Wang WH; Huang CH; Chen YH; Lu PL
    J Microbiol Immunol Infect; 2018 Feb; 51(1):88-93. PubMed ID: 28698044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting.
    Niward K; Davies Forsman L; Bruchfeld J; Chryssanthou E; Carlström O; Alomari T; Carlsson B; Pohanka A; Mansjö M; Jonsson Nordvall M; Johansson AG; Eliasson E; Werngren J; Paues J; Simonsson USH; Schön T
    J Antimicrob Chemother; 2018 Oct; 73(10):2838-2845. PubMed ID: 30124844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prevalence and risk factors on the resistance related to second-line drugs among multi-drug resistant tuberculosis cases in Shanghai, China].
    Li J; Zhang YY; Gui XH; Yuan ZA; Pan QC; Mei J; Shen X
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Aug; 33(8):796-8. PubMed ID: 22967331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.
    Che Y; Bo D; Lin X; Chen T; He T; Lin Y
    BMC Infect Dis; 2021 Jun; 21(1):605. PubMed ID: 34171989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the broth microdilution plate methodology for susceptibility testing of Mycobacterium tuberculosis in Peru.
    Puyén ZM; Santos-Lázaro D; Vigo AN; Coronel J; Alarcón MJ; Cotrina VV; Moore DAJ
    BMC Infect Dis; 2022 Aug; 22(1):705. PubMed ID: 36002805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tuberculosis drug resistance and outcomes among tuberculosis inpatients in Lilongwe, Malawi.
    Vorkas C; Kayira D; van der Horst C; Hoffman I; Hosseinipour M; Kanyemba C; Nguluwe N; Chikaonda T; Kalikhoka M; Kalaundi D; Namarika D; Gilligan P; Krysiak R
    Malawi Med J; 2012 Jun; 24(2):21-4. PubMed ID: 23638265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics and pharmacodynamics of investigational regimens' drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial.
    Nyang'wa BT; Kloprogge F; Moore DAJ; Bustinduy A; Motta I; Berry C; Davies GR
    BMJ Open; 2021 Sep; 11(9):e047185. PubMed ID: 34489274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting.
    Metcalfe J; Bacchetti P; Esmail A; Reckers A; Aguilar D; Wen A; Huo S; Muyindike WR; Hahn JA; Dheda K; Gandhi M; Gerona R
    BMC Infect Dis; 2021 Jan; 21(1):99. PubMed ID: 33482745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of second-line antituberculosis drug susceptibilities of multidrug-resistant Mycobacterium tuberculosis complex isolates by E-test method].
    Şimşek H; Tarhan G; Cesur S
    Mikrobiyol Bul; 2015 Jan; 49(1):47-55. PubMed ID: 25706730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.